These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 9355667)

  • 1. Potential of densitometric measurement in selected pediatric subject.
    Lorenc RS; Matusik H; Olszaniecka M; Lebiedowski M
    Acta Univ Carol Med (Praha); 1994; 40(1-4):23-8. PubMed ID: 9355667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of the bone mineral density investigation through measuring of peripheral dual-energetic x-ray absorption in prevention of fractures in children with osteogenesis imperfecta].
    Saganelidze KhZ
    Georgian Med News; 2005 Mar; (120):61-4. PubMed ID: 15855703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total body bone mineral and tartrate-resistant acid phosphatase levels in type I and III osteogenesis imperfecta.
    Rico H; Revilla M; Iritia M; Arribas I; Fernando Villa L
    Miner Electrolyte Metab; 1991; 17(6):396-8. PubMed ID: 1823391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction models for evaluation of total-body bone mass with dual-energy X-ray absorptiometry among children and adolescents.
    Horlick M; Wang J; Pierson RN; Thornton JC
    Pediatrics; 2004 Sep; 114(3):e337-45. PubMed ID: 15342895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical observation of osteoporosis in adolescents].
    Chlebna-Sokół D; Jakubowska E; Sikora A
    Przegl Lek; 2000; 57(2):83-6. PubMed ID: 10907348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of bone mineral density with dual x-ray absorptiometry for osteoporosis in children with bladder augmentation.
    Abeş M; Sarihan H; Madenci E
    J Pediatr Surg; 2003 Feb; 38(2):230-2. PubMed ID: 12596110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relationship between bone mineral content and growth disorders in children with juvenile idiopathic arthritis].
    Górska A; Urban M; Konstantynowicz J; Bartnicka M; Chlabicz S; Górski S; Kaczmarski M
    Pol Merkur Lekarski; 2008 Mar; 24(141):227-30. PubMed ID: 18634288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Osteoporosis in children].
    Lorenc RS; Olszaniecka M
    Przegl Lek; 2000; 57(2):127-30. PubMed ID: 10907357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Just taller or more bone? The impact of growth hormone on osteogenesis imperfecta and idiopathic juvenile osteoporosis.
    Wright NM
    J Pediatr Endocrinol Metab; 2000 Sep; 13 Suppl 2():999-1002. PubMed ID: 11086654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Idiopathic and secondary osteoporosis in childhood].
    Rossi F; Perrotta S; Falcone E; Gimigliano F; Iodice M; Vetrella S; Iolascon G
    Minerva Pediatr; 2005 Oct; 57(5):203-11. PubMed ID: 16205605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dynamics of the course of idiopathic juvenile osteoporosis].
    Olszaniecka M; Lebiedowski M; Lorenc RS; Arasimowicz E; Graff K; Madej M; Marowska J; Matusik H; Tałajko A; Wieczorek E
    Pol Tyg Lek; 1993 Nov; 48 Suppl 3():20-3. PubMed ID: 8309831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
    Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
    Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alendronate treatment in osteogenesis imperfecta.
    Madenci E; Yilmaz K; Yilmaz M; Coskun Y
    J Clin Rheumatol; 2006 Apr; 12(2):53-6. PubMed ID: 16601536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
    Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC
    Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of interleukin-1 and -6 in the etiopathogenesis of idiopathic osteoporosis and osteopenia in children.
    Rusińska A; Chlebna-Sokół D
    Arch Immunol Ther Exp (Warsz); 2005; 53(3):257-65. PubMed ID: 15995586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-I and mineral metabolism markers in children with idiopathic decrease in bone mass.
    Rusińska A; Chlebna-Sokół D
    Clin Chim Acta; 2006 Apr; 366(1-2):257-63. PubMed ID: 16330010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum insulin/like growth factor I, bone mineral density and biochemical markers of bone metabolism in children with idiopathic osteoporosis.
    Chlebna-Sokol D; Rusinska A
    Endocr Regul; 2001 Dec; 35(4):201-8. PubMed ID: 11858767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T; Turan S; Guran T; Bereket A
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence that abnormal high bone mineralization in growing children with osteogenesis imperfecta is not associated with specific collagen mutations.
    Roschger P; Fratzl-Zelman N; Misof BM; Glorieux FH; Klaushofer K; Rauch F
    Calcif Tissue Int; 2008 Apr; 82(4):263-70. PubMed ID: 18311573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.